Eclitasertib

N/A

Report date: 2023/05/18 20:00:22
NME

Base Information

Drug NameEclitasertib
Drug Alias NameDNL-758SAR-443122
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor-interacting serine/threonine-protein kinase 1 inhibitors
TargetsReceptor-interacting serine/threonine-protein kinase 1
Therapy Area/IndicationsLupus Erythematosus, CutaneousColitis, UlcerativeCoronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSanofiDenali Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiSanofi-Aventis Recherche & DeveloppementSanofi (China) Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, CutaneousColitis, Ulcerative
Inactive IndicationsCoronavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A